• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

aparna.rao@unimelb.edu.au

Credentials


Position
Honorary Conjoint Fellow
The Sir Peter MacCallum Department of Oncology
ORCID

0000-0002-6394-0011

Dr Aparna Rao

Honorary Conjoint Fellow
The Sir Peter MacCallum Department of Oncology

39 Scholarly works
1 Projects

HIGHLIGHTS

  • 2026

    Journal article

    Tumor-resident T cells and dendritic cells form an in situ archetype during immunotherapy response in melanoma.
    DOI: 10.1038/s41467-026-74076-y
  • 2026

    Journal article

    Real world outcomes of neoadjuvant immune checkpoint blockade (ICB) for resectable stage III melanoma: Pathologic response and FDG PET/CT correlates.
    DOI: 10.1200/jco.2026.44.16_suppl.9569
  • 2026

    Journal article

    Resistance to anti-PD-1 immunotherapy for stage III and IV melanoma: a global chart review study
    DOI: 10.1136/jitc-2025-014564
  • 2025

    Journal article

    Long-term clinical outcomes of bevacizumab for treatment of stereotactic radiosurgery-induced radiation necrosis in patients with brain metastases
    DOI: 10.1007/s11060-025-05121-x
  • 2025

    Journal article

    1637P FDG PET/CT response as a predictive biomarker of long-term outcomes and patterns of recurrence to immune checkpoint inhibitor (ICI) therapy in unresectable cutaneous melanoma
    DOI: 10.1016/j.annonc.2025.08.2265
  • 2025

    Research grants (ARC, NHMRC, MRFF)

    Identifying Novel Metabolic Biomarkers and Therapeutic Targets in Patients With Melanoma
  • 2014

    Journal article

    Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis
    DOI: 10.1158/2159-8290.CD-13-0440
Aparna Rao

RECENT SCHOLARLY WORKS

  • 2025

    Conference Proceedings

    1636P Gonadal toxicity in men receiving immune checkpoint inhibitors for melanoma
    DOI: 10.1016/j.annonc.2025.08.2264
  • 2025

    Journal article

    Conservation and divergence of metabolic phenotypes between patient tumours and matched xenografts
    DOI: 10.1038/s42255-025-01338-2
  • 2025

    Journal article

    Resistance to anti-PD-1 immunotherapy for stage III and IV melanoma: Results from a global multi-site chart review.
    DOI: 10.1200/jco.2025.43.16_suppl.9532
  • 2025

    Conference Proceedings

    Financial toxicity and employment outcomes in people with melanoma receiving adjuvant therapies.
    DOI: 10.1200/jco.2025.43.16_suppl.9577
  • 2025

    Journal article

    Patient-reported acute and chronic toxicities from adjuvant therapies post resection of melanoma.
    DOI: 10.1200/jco.2025.43.16_suppl.e21568

Acknowledgement of Country

We acknowledge Aboriginal and Torres Strait Islander people as the Traditional Owners of the unceded lands on which we work, learn and live. We pay respect to Elders past, present and future, and acknowledge the importance of Indigenous knowledge in the Academy.

Read about our Indigenous priorities

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Campus locations  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia

facebookIconlinkedinIconinstagramIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy

CRICOS number: 00116K     ABN: 84 002 705 224